Brokerages Set Masimo Co. (NASDAQ:MASI) Target Price at $179.67

Masimo Co. (NASDAQ:MASI) has been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $179.67.

A number of equities analysts have recently commented on MASI shares. Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company lifted their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. BTIG Research increased their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Piper Sandler boosted their price target on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd.

Institutional Trading of Masimo

Large investors have recently made changes to their positions in the business. Blue Trust Inc. lifted its position in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares in the last quarter. NBC Securities Inc. lifted its position in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares in the last quarter. MML Investors Services LLC grew its stake in shares of Masimo by 4.9% during the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 96 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares in the last quarter. Finally, Assetmark Inc. raised its position in Masimo by 12.7% in the 3rd quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock worth $158,000 after purchasing an additional 133 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Stock Up 2.7 %

MASI stock opened at $175.18 on Friday. Masimo has a twelve month low of $101.61 and a twelve month high of $180.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market cap of $9.38 billion, a PE ratio of 120.81 and a beta of 1.01. The business’s 50-day simple moving average is $170.75 and its 200 day simple moving average is $143.51.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 EPS. On average, research analysts anticipate that Masimo will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.